Sanofi (NASDAQ:SNY) Shares Purchased by Northern Trust Corp

Northern Trust Corp increased its position in Sanofi (NASDAQ:SNY - Free Report) by 44.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,930,560 shares of the company's stock after buying an additional 597,959 shares during the period. Northern Trust Corp owned about 0.08% of Sanofi worth $93,111,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Arkadios Wealth Advisors increased its position in Sanofi by 19.0% in the fourth quarter. Arkadios Wealth Advisors now owns 4,709 shares of the company's stock worth $227,000 after purchasing an additional 751 shares during the last quarter. Kentucky Trust Co bought a new position in shares of Sanofi in the 4th quarter valued at about $436,000. Park Avenue Securities LLC grew its position in Sanofi by 14.3% in the fourth quarter. Park Avenue Securities LLC now owns 68,982 shares of the company's stock worth $3,327,000 after acquiring an additional 8,615 shares in the last quarter. Van ECK Associates Corp increased its stake in Sanofi by 18.1% during the fourth quarter. Van ECK Associates Corp now owns 662,762 shares of the company's stock worth $31,965,000 after acquiring an additional 101,726 shares during the last quarter. Finally, Sound Income Strategies LLC increased its position in Sanofi by 156,520.9% during the fourth quarter. Sound Income Strategies LLC now owns 67,347 shares of the company's stock valued at $3,248,000 after acquiring an additional 67,304 shares during the last quarter. Hedge funds and other institutional investors own 14.04% of the company's stock.

Sanofi Stock Performance

Shares of SNY traded down $0.88 during mid-day trading on Wednesday, hitting $52.27. 2,128,719 shares of the company's stock were exchanged, compared to its average volume of 2,359,759. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15. The business's 50 day moving average is $54.46 and its two-hundred day moving average is $52.04. Sanofi has a fifty-two week low of $45.80 and a fifty-two week high of $60.12. The firm has a market capitalization of $132.05 billion, a P/E ratio of 20.99, a P/E/G ratio of 1.01 and a beta of 0.55.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. The business had revenue of $10.41 billion during the quarter, compared to analysts' expectations of $9.79 billion. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. The company's quarterly revenue was down 11.0% compared to the same quarter last year. During the same period last year, the firm earned $1.78 EPS. On average, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.

Sanofi Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Investors of record on Friday, May 9th will be given a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's payout ratio is currently 57.14%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Sanford C. Bernstein upgraded Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. BNP Paribas assumed coverage on shares of Sanofi in a report on Tuesday, April 15th. They set an "outperform" rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group began coverage on Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Three analysts have rated the stock with a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $63.33.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.